A Move To Fund The NIH's 'Also-Rans'

Tucked in among the multipage, multicolored ads touting medications for baldness, hypertension, and assorted infections in the New England Journal of Medicine on November 17, 1988, was a one-column notice in plain, black and white describing an innovative research grant program. The ad, placed by the Cystic Fibrosis Foundation (CFF) of Bethesda, Md., called for proposals from investigators whose grant applications to the National Institutes of Health had received the NIH’s dreaded verdi

Murray Saffran
Mar 5, 1989

Tucked in among the multipage, multicolored ads touting medications for baldness, hypertension, and assorted infections in the New England Journal of Medicine on November 17, 1988, was a one-column notice in plain, black and white describing an innovative research grant program. The ad, placed by the Cystic Fibrosis Foundation (CFF) of Bethesda, Md., called for proposals from investigators whose grant applications to the National Institutes of Health had received the NIH’s dreaded verdict of approved—but with anonfundable priority. According to the journal ad, if the “good-but-not-quite-good-enough” proposal pertained to cystic fibrosis, CFF might be willing to fund it. As far as CFF is aware, it is the first foundation to try this approach in a formal, systematic way.

The experiment comes not a minute too soon for some researchers in the biomedical community. In recent years, NIH has been able to fund fewer and fewer of the applications it approves...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?